Myasthenia Gravis Clinical Trials

• Male or female patient aged ≥18 years at screening.

• Patients have prior confirmed diagnosis of gMG with generalized muscle weakness (typical pattern of weakness meeting the clinical criteria for diagnosis of MG as defined by the Myasthenia Gravis Foundation of America (MGFA) clinical classification II-IV.

• Patients have positive antibodies against AChR or MuSK at screening.

• MG-ADL score ≥6 points at screening and baseline with ocular-related score \<50% of the total score.

• QMG score ≥8 points, and ≥ 4 items score at least 2 points at screening and baseline.